BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25297731)

  • 21. Genomics in acute myeloid leukemia: from identification to personalization.
    Martin JM; Winer ES
    R I Med J (2013); 2015 Nov; 98(11):27-30. PubMed ID: 26517252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
    Sakata-Yanagimoto M; Enami T; Yoshida K; Shiraishi Y; Ishii R; Miyake Y; Muto H; Tsuyama N; Sato-Otsubo A; Okuno Y; Sakata S; Kamada Y; Nakamoto-Matsubara R; Tran NB; Izutsu K; Sato Y; Ohta Y; Furuta J; Shimizu S; Komeno T; Sato Y; Ito T; Noguchi M; Noguchi E; Sanada M; Chiba K; Tanaka H; Suzukawa K; Nanmoku T; Hasegawa Y; Nureki O; Miyano S; Nakamura N; Takeuchi K; Ogawa S; Chiba S
    Nat Genet; 2014 Feb; 46(2):171-5. PubMed ID: 24413737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Aberrant cytosine hydroxymethylation in hematologic malignancies].
    Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2013 May; 54(5):423-30. PubMed ID: 23727679
    [No Abstract]   [Full Text] [Related]  

  • 24. Alterations to
    Venugopal K; Feng Y; Shabashvili D; Guryanova OA
    Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
    Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
    Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.
    Wang M; Zhang S; Chuang SS; Ashton-Key M; Ochoa E; Bolli N; Vassiliou G; Gao Z; Du MQ
    Oncotarget; 2017 Mar; 8(11):17763-17770. PubMed ID: 28148900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
    Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
    Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.
    Wakita S; Yamaguchi H; Omori I; Terada K; Ueda T; Manabe E; Kurosawa S; Iida S; Ibaraki T; Sato Y; Todoroki T; Hirakawa T; Ryotokuji T; Arai K; Kitano T; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2013 Apr; 27(5):1044-52. PubMed ID: 23135354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic modifiers in normal and malignant hematopoiesis.
    Haladyna JN; Yamauchi T; Neff T; Bernt KM
    Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis.
    Saiki R; Momozawa Y; Nannya Y; Nakagawa MM; Ochi Y; Yoshizato T; Terao C; Kuroda Y; Shiraishi Y; Chiba K; Tanaka H; Niida A; Imoto S; Matsuda K; Morisaki T; Murakami Y; Kamatani Y; Matsuda S; Kubo M; Miyano S; Makishima H; Ogawa S
    Nat Med; 2021 Jul; 27(7):1239-1249. PubMed ID: 34239136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
    Zhu C; Ma Y; Xu XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
    Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
    Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.
    Fukumoto K; Nguyen TB; Chiba S; Sakata-Yanagimoto M
    Cancer Sci; 2018 Mar; 109(3):490-496. PubMed ID: 28889481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic aberrations in myeloid malignancies (Review).
    Takahashi S
    Int J Mol Med; 2013 Sep; 32(3):532-8. PubMed ID: 23760684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.
    Abdel-Wahab O
    Hematology; 2012 Apr; 17 Suppl 1():S39-42. PubMed ID: 22507776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.
    Perugini M; Iarossi DG; Kok CH; Cummings N; Diakiw SM; Brown AL; Danner S; Bardy P; Bik To L; Wei AH; Lewis ID; D'Andrea RJ
    Leukemia; 2013 Jul; 27(7):1588-92. PubMed ID: 23187294
    [No Abstract]   [Full Text] [Related]  

  • 37. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNMT3A in haematological malignancies.
    Yang L; Rau R; Goodell MA
    Nat Rev Cancer; 2015 Mar; 15(3):152-65. PubMed ID: 25693834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
    Zhang X; Wang X; Wang XQD; Su J; Putluri N; Zhou T; Qu Y; Jeong M; Guzman A; Rosas C; Huang Y; Sreekumar A; Li W; Goodell MA
    Blood; 2020 Mar; 135(11):845-856. PubMed ID: 31932841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
    Patel JP; Levine RL
    Hematology Am Soc Hematol Educ Program; 2012; 2012():28-34. PubMed ID: 23233557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.